Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications
about
Antibody promiscuity: Understanding the paradigm shift in antigen recognitionStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeAutoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 EpitopeRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityMax Bergmann lecture protein epitope mimetics in the age of structural vaccinologyComputational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residuesRelationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining regionRole of humoral immunity in host defense against HIV.Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost studyThermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Equivalent T cell epitope promiscuity in ecologically diverse human pathogens.Combining spatial and chemical information for clustering pharmacophores.Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralizationBinding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virionsNeutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.Computer-Aided Approaches for Targeting HIVgp41.The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimerAblation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.BlockLogo: visualization of peptide and sequence motif conservation.New approaches to vaccination
P2860
Q26801316-954D6159-A2CA-48EA-B9AA-509EF9884F7FQ27675260-03B60155-DEAD-4027-9241-B2B8E54EAEFEQ27680125-AA845E12-914F-4E14-84FB-BA0C9156D375Q27681352-C8ADF4F3-7AB1-409C-93F9-2A273AE36A5EQ28484544-692B6CD8-A5C2-4EE4-A741-A7C769809873Q30155145-30D03321-D740-4DFC-B4B9-A8493A3E54ECQ30644992-CD748B77-5BE5-49DE-A6EB-53BF0EB39732Q33676600-4679ADD6-E1BC-433D-BE54-B45F2403A0EFQ33898131-B47C2E4B-9F38-4218-B9A4-F43E6C263541Q34312108-923E9C95-451B-43DC-B615-05EBD9EC6F13Q34389587-51610032-56F7-4D3E-9F94-E01E7B7F5A0AQ34488183-D1ADABB4-0FB3-4A91-946A-F766DAA23CC5Q34951888-14C7807F-E1E5-4A72-BEC9-553C19C62440Q35529213-9E7E4402-02CE-47F9-B88E-B6CDD7D0D78DQ35660279-7083EA84-CA05-4BFA-A194-B35FFFC44C45Q35689608-7974DD5B-68A4-477E-8DA3-5086E49B588DQ35826306-906A7BCD-96F5-47E9-9CA6-D82F6E141F92Q36693991-FA9FEC3E-8538-44CC-B538-8348BC352EF0Q37762275-08FE904E-ADEC-41E6-A3BC-149D53CF569EQ38046828-9E55C893-0B25-4AB9-8C88-5E5BAAA22B45Q38050485-5E69A60C-7AA2-44B8-A4EB-A97F3B2FC412Q38111393-31E1CE0F-4E75-415A-9773-5A6928964AA2Q38806886-F92E55DB-105D-4D91-BF7F-77C0CA985366Q39136039-8957CD58-A69B-491F-958A-116B5DFCC843Q39949085-7F92D896-72FC-4019-A8D1-B04F3FFFA531Q40340474-F701EBAC-B57C-4229-8C97-36FFFB66A277Q42097385-61A9E048-C08E-44C9-9A7F-390E5A2F9AABQ57170110-0CC93AA9-942E-4F7C-A29C-D09A49CF3793
P2860
Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Crystallographic Definition of ...... 5: Vaccine Design Implications
@ast
Crystallographic Definition of ...... 5: Vaccine Design Implications
@en
Crystallographic Definition of ...... 5: Vaccine Design Implications
@nl
type
label
Crystallographic Definition of ...... 5: Vaccine Design Implications
@ast
Crystallographic Definition of ...... 5: Vaccine Design Implications
@en
Crystallographic Definition of ...... 5: Vaccine Design Implications
@nl
prefLabel
Crystallographic Definition of ...... 5: Vaccine Design Implications
@ast
Crystallographic Definition of ...... 5: Vaccine Design Implications
@en
Crystallographic Definition of ...... 5: Vaccine Design Implications
@nl
P2860
P356
P1433
P1476
Crystallographic Definition of ...... 5: Vaccine Design Implications
@en
P2093
Rosemary C Hynes
Steve Bryson
P2860
P304
P356
10.1128/JVI.01604-09
P577
2009-11-01T00:00:00Z